Phase I Studies of Vorinostat With Ixazomib or Pazopanib Imply a Role of Antiangiogenesis-Based Therapy for TP53 Mutant Malignancies

Scientific Reports - United Kingdom
doi 10.1038/s41598-020-58366-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Outcome Analysis of Phase I Trial Patients With Metastatic KRAS and/or TP53 Mutant Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

A Phase I Trial of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL0916)

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2012English

Phase 1 Study of Ixazomib, an Investigational Proteasome Inhibitor, in Advanced Non-Hematologic Malignancies

Investigational New Drugs
OncologyPharmacology
2015English

Phase I Trial of Vorinostat Added to Chemoradiation With Capecitabine in Pancreatic Cancer

Radiotherapy and Oncology
Nuclear MedicineOncologyRadiologyHematologyImaging
2016English

A Phase I Study of Indoximod in Patients With Advanced Malignancies

Oncotarget
Oncology
2016English

Results of a Prospective Phase 2 Study of Pazopanib in Patients With Surgically Unresectable or Metastatic Chondrosarcoma

Cancer
Cancer ResearchOncology
2019English

A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas

American Journal of Hematology
Hematology
2017English

Activation of TAp73 and Inhibition of TrxR for Improved Cancer Therapy in TP53 Mutant Pancreatic Tumors

Future Science OA
MedicineBiotechnology
2019English

Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy